» Articles » PMID: 23653679

Antidepressant Treatment Outcome Depends on the Quality of the Living Environment: a Pre-clinical Investigation in Mice

Overview
Journal PLoS One
Date 2013 May 9
PMID 23653679
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Antidepressants represent the standard treatment for major depression. However, their efficacy is variable and incomplete. A growing number of studies suggest that the environment plays a major role in determining the efficacy of these drugs, specifically of selective serotonin reuptake inhibitors (SSRI). A recent hypothesis posits that the increase in serotonin levels induced by SSRI may not affect mood per se, but enhances neural plasticity and, consequently, renders the individual more susceptible to the influence of the environment. Thus, SSRI administration in a favorable environment would lead to a reduction of symptoms, while in a stressful environment might lead to a worse prognosis. To test this hypothesis, we treated C57BL/6 adult male mice with chronic fluoxetine while exposing them to either (i) an enriched environment, after exposure to a chronic stress period aimed at inducing a depression-like phenotype, or (ii) a stressful environment. Anhedonia, brain BDNF and circulating corticosterone levels, considered endophenotypes of depression, were investigated. Mice treated with fluoxetine in an enriched condition improved their depression-like phenotype compared to controls, displaying higher saccharin preference, higher brain BDNF levels and reduced corticosterone levels. By contrast, when chronic fluoxetine administration occurred in a stressful condition, mice showed a more distinct worsening of the depression-like profile, displaying a faster decrease of saccharin preference, lower brain BDNF levels and increased corticosterone levels. Our findings suggest that the effect of SSRI on depression-like phenotypes in mice is not determined by the drug per se but is induced by the drug and driven by the environment. These findings may be helpful to explain variable effects of SSRI found in clinical practice and to device strategies aimed at enhancing their efficacy by means of controlling environmental conditions.

Citing Articles

More and Less Fear in Serotonin Transporter Knockout Mice.

Lima J, Panayi M, Sharp T, McHugh S, Bannerman D Genes Brain Behav. 2025; 24(1):e70016.

PMID: 39917838 PMC: 11803413. DOI: 10.1111/gbb.70016.


Beyond the serotonin deficit hypothesis: communicating a neuroplasticity framework of major depressive disorder.

Page C, Epperson C, Novick A, Duffy K, Thompson S Mol Psychiatry. 2024; 29(12):3802-3813.

PMID: 38816586 PMC: 11692567. DOI: 10.1038/s41380-024-02625-2.


Comparing the effect of fluoxetine, escitalopram, and sertraline, on the level of BDNF and depression in preclinical and clinical studies: a systematic review.

Talaee N, Azadvar S, Khodadadi S, Abbasi N, Asli-Pashaki Z, Mirabzadeh Y Eur J Clin Pharmacol. 2024; 80(7):983-1016.

PMID: 38558317 DOI: 10.1007/s00228-024-03680-y.


Digital Therapeutics for Improving Effectiveness of Pharmaceutical Drugs and Biological Products: Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases.

Biskupiak Z, Ha V, Rohaj A, Bulaj G J Clin Med. 2024; 13(2).

PMID: 38256537 PMC: 10816409. DOI: 10.3390/jcm13020403.


IntelliCage: the development and perspectives of a mouse- and user-friendly automated behavioral test system.

Lipp H, Krackow S, Turkes E, Benner S, Endo T, Russig H Front Behav Neurosci. 2024; 17:1270538.

PMID: 38235003 PMC: 10793385. DOI: 10.3389/fnbeh.2023.1270538.


References
1.
Fournier J, DeRubeis R, Hollon S, Dimidjian S, Amsterdam J, Shelton R . Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010; 303(1):47-53. PMC: 3712503. DOI: 10.1001/jama.2009.1943. View

2.
Kozisek M, Middlemas D, Bylund D . Brain-derived neurotrophic factor and its receptor tropomyosin-related kinase B in the mechanism of action of antidepressant therapies. Pharmacol Ther. 2007; 117(1):30-51. DOI: 10.1016/j.pharmthera.2007.07.001. View

3.
Anacker C, Zunszain P, Carvalho L, Pariante C . The glucocorticoid receptor: pivot of depression and of antidepressant treatment?. Psychoneuroendocrinology. 2010; 36(3):415-25. PMC: 3513407. DOI: 10.1016/j.psyneuen.2010.03.007. View

4.
Jacobsen J, Mork A . The effect of escitalopram, desipramine, electroconvulsive seizures and lithium on brain-derived neurotrophic factor mRNA and protein expression in the rat brain and the correlation to 5-HT and 5-HIAA levels. Brain Res. 2004; 1024(1-2):183-92. DOI: 10.1016/j.brainres.2004.07.065. View

5.
Uys J, Muller C, Marais L, Harvey B, Stein D, Daniels W . Early life trauma decreases glucocorticoid receptors in rat dentate gyrus upon adult re-stress: reversal by escitalopram. Neuroscience. 2005; 137(2):619-25. DOI: 10.1016/j.neuroscience.2005.08.089. View